Sales & Marketing Evolving HCP access requires a new connected approach to bui... Specialty medicines – treatments designed for very small patient populations with complex and rare conditions – are on the rise.
R&D In conversation with Chris Moore: Declining HCP access During the 10th anniversary of the Veeva R&D and Quality Summit, held in Madrid in June, web editor Nicole Raleigh sat down with Chris Moore, president of Europe for Veeva Systems, to d
Market Access Shifting HCP access calls for new field tactics globally Even before COVID-19 pushed access to an all-time low, access had been declining
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.